The utility of ADMIRE-HF risk score in predicting serious arrhythmic events in heart failure patients: Incremental prognostic benefit of cardiac 123I-mIBG scintigraphy

Journal of Nuclear Cardiology

Volumn 21, Issue 4, 2014, Pages 756-762

  Al Badarin, Firas J ^a,b,c   Wimmer, Alan P ^a,c   Kennedy, Kevin F ^a   Jacobson, Arnold F ^d   Bateman, Timothy M ^a,c,e  

^a SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^b Prairie Heart Institute of Southern Illinois   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^d GE Healthcare Life Sciences   (United States)

^e ASPIRE Foundation   (United States)

Author keywords

Heart failure; mIBG scintigraphy; sudden cardiac death

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; TETROFOSMIN TC 99M; (3 IODOBENZYL)GUANIDINE;

ADREVIEW MYOCARDIAL IMAGING FOR RISK EVALUATION IN HEART FAILURE RISK SCORE; ADULT; ARTICLE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HEART ARREST; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART SCINTISCANNING; HEART TO MEDIASTINUM RATIO; HEART VENTRICLE TACHYCARDIA; HIGH RISK POPULATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAJOR CLINICAL STUDY; MALE; NERVE CONDUCTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RESUSCITATION; RISK ASSESSMENT; SCORING SYSTEM; SUDDEN CARDIAC DEATH; SYMPATHETIC NERVE; SYSTOLIC BLOOD PRESSURE; AGED; ARRHYTHMIAS, CARDIAC; COMPLICATION; DEATH, SUDDEN, CARDIAC; DIAGNOSTIC USE; HEART; MIDDLE AGED; SCINTISCANNING; SYSTOLE;

3-IODOBENZYLGUANIDINE; ADULT; AGED; ARRHYTHMIAS, CARDIAC; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEART; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RISK ASSESSMENT; SYSTOLE;

EID: 84905083779     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-014-9919-z     Document Type: Article

References (21)

1. Ezekowitz JA, Armstrong PW, McAlister FA. Implantable cardioverter defibrillators in primary and secondary prevention: A systematic review of randomized, controlled trials. Ann Intern Med 2003;138:445-52.
2. Nanthakumar K, Epstein AE, Kay GN, Plumb VJ, Lee DS. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: A pooled analysis of 10 primary prevention trials. J Am Coll Cardiol 2004;44:2166-72. (Pubitemid 39576036)
3. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008;51:e1-62.
4. Buxton AE, Lee KL, Hafley GE, Pires LA, Fisher JD, Gold MR, et al. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: Lessons from the MUSTT study. J Am Coll Cardiol 2007;50:1150-7. (Pubitemid 47375017)
5. Goldberger JJ, Cain ME, Hohnloser SH, Kadish AH, Knight BP, Lauer MS, et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. A scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. J Am Coll Cardiol 2008;52:1179-99.
6. Moss AJ, Greenberg H, Case RB, Zareba W, Hall WJ, Brown MW, et al. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation 2004;110:3760-5. (Pubitemid 40023973)
7. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008;359:1009-17.
8. Buxton AE. Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator? Not everyone with an ejection fraction ≤30% should receive an implantable cardioverter- defibrillator. Circulation 2005;111:2537-49; discussion -49.
9. Sisson JC, Wieland DM. Radiolabeled meta-iodobenzylguanidine: Pharmacology and clinical studies. Am J Physiol Imaging 1986;1:96-103. (Pubitemid 17188385)
10. Tamaki S, Yamada T, Okuyama Y, Morita T, Sanada S, Tsukamoto Y, et al. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: Results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol 2009;53:426-35.
11. Nagahara D, Nakata T, Hashimoto A, Wakabayashi T, Kyuma M, Noda R, et al. Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function. J Nucl Med 2008;49:225-33. (Pubitemid 351225660)
12. Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: Insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging 2008;35:535-46.
13. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010;55:2212-21.
14. 123I-mIBG scintigraphy to predict inducibility of ventricular arrhythmias on cardiac electrophysiology testing: A prospective multicenter pilot study. Circ Cardiovasc Imaging 2008;1:131-40.
15. Boogers MJ, Borleffs CJ, Henneman MM, van Bommel RJ, van Ramshorst J, Boersma E, et al. Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverterdefibrillator patients. J Am Coll Cardiol 2010;55:2769-77.
16. Jacobson AF, Lombard J, Banerjee G, Camici PG. 123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: Design of two prospective multicenter international trials. J Nucl Cardiol 2009;16:113-21.
17. Holly TA, Abbott BG, Al-Mallah M, Calnon DA, Cohen MC, DiFilippo FP, et al. Single photon-emission computed tomography. J Nucl Cardiol 2010;17:941-73.
18. Sullivan LM, Massaro JM, D'Agostino RB Sr. Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med 2004;23:1631-60. (Pubitemid 38660414)
19. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72. (Pubitemid 351193639)
20. Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He H, et al. Risk stratification for primary implantation of a cardioverterdefibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2008;51:288-96.
21. Klein G, Lissel C, Fuchs AC, Gardiwal A, Oswald H, Desousa M, et al. Predictors of VT/VF-occurrence in ICD patients: Results from the PROFIT-Study. Europace 2006;8:618-24. (Pubitemid 44295759)